481 related articles for article (PubMed ID: 29724815)
21. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
22. Clinical assays for assessment of homologous recombination DNA repair deficiency.
Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
[TBL] [Abstract][Full Text] [Related]
23. Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
Zhao EY; Shen Y; Pleasance E; Kasaian K; Leelakumari S; Jones M; Bose P; Ch'ng C; Reisle C; Eirew P; Corbett R; Mungall KL; Thiessen N; Ma Y; Schein JE; Mungall AJ; Zhao Y; Moore RA; Den Brok W; Wilson S; Villa D; Shenkier T; Lohrisch C; Chia S; Yip S; Gelmon K; Lim H; Renouf D; Sun S; Schrader KA; Young S; Bosdet I; Karsan A; Laskin J; Marra MA; Jones SJM
Clin Cancer Res; 2017 Dec; 23(24):7521-7530. PubMed ID: 29246904
[No Abstract] [Full Text] [Related]
24. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
25. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
26. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Poveda A; Lheureux S; Colombo N; Cibula D; Lindemann K; Weberpals J; Bjurberg M; Oaknin A; Sikorska M; González-Martín A; Madry R; Pérez MJR; Ledermann J; Davidson R; Blakeley C; Bennett J; Barnicle A; Škof E
Gynecol Oncol; 2022 Mar; 164(3):498-504. PubMed ID: 35063276
[TBL] [Abstract][Full Text] [Related]
27. High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
Aziz D; Lee C; Chin V; Fernandez KJ; Phan Z; ; ; Waring P; Caldon CE
J Pathol Clin Res; 2022 Jul; 8(4):355-370. PubMed ID: 35384378
[TBL] [Abstract][Full Text] [Related]
28. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
[TBL] [Abstract][Full Text] [Related]
29. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
Aziz D; Etemadmoghadam D; Caldon CE; Au-Yeung G; Deng N; Hutchinson R; ; Bowtell D; Waring P
Gynecol Oncol; 2018 Nov; 151(2):327-336. PubMed ID: 30209015
[TBL] [Abstract][Full Text] [Related]
30. Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay.
Scaglione GL; Pignata S; Pettinato A; Paolillo C; Califano D; Scandurra G; Lombardo V; Di Gaudio F; Pecorino B; Mereu L; Scollo P; Capoluongo ED
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069422
[TBL] [Abstract][Full Text] [Related]
31. Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and
Telli ML; Chu C; Badve SS; Vinayak S; Silver DP; Isakoff SJ; Kaklamani V; Gradishar W; Stearns V; Connolly RM; Ford JM; Gruber JJ; Adams S; Garber J; Tung N; Neff C; Bernhisel R; Timms KM; Richardson AL
Clin Cancer Res; 2020 Jun; 26(11):2704-2710. PubMed ID: 31796517
[TBL] [Abstract][Full Text] [Related]
32. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
[TBL] [Abstract][Full Text] [Related]
33. Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
Koole SN; Schouten PC; Hauke J; Kluin RJC; Nederlof P; Richters LK; Krebsbach G; Sikorska K; Alkemade M; Opdam M; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; Mom CH; Arts HJG; van Ham M; van Dam P; Vuylsteke P; Sanders J; Horlings HM; van de Vijver KK; Hahnen E; van Driel WJ; Schmutzler R; Sonke GS; Linn SC
Int J Cancer; 2022 Oct; 151(8):1394-1404. PubMed ID: 35583992
[TBL] [Abstract][Full Text] [Related]
34. Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.
von Wahlde MK; Timms KM; Chagpar A; Wali VB; Jiang T; Bossuyt V; Saglam O; Reid J; Gutin A; Neff C; Lanchbury JS; Hatzis C; Hofstatter E; Pusztai L
Clin Cancer Res; 2017 Mar; 23(5):1193-1199. PubMed ID: 27601588
[No Abstract] [Full Text] [Related]
35. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
Pothuri B
Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965
[TBL] [Abstract][Full Text] [Related]
36. Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
Landen CN; Molinero L; Hamidi H; Sehouli J; Miller A; Moore KN; Taskiran C; Bookman M; Lindemann K; Anderson C; Berger R; Myers T; Beiner M; Reid T; Van Nieuwenhuysen E; Green A; Okamoto A; Aghajanian C; Thaker PH; Blank SV; Khor VK; Chang CW; Lin YG; Pignata S
Clin Cancer Res; 2023 May; 29(9):1698-1707. PubMed ID: 36595569
[TBL] [Abstract][Full Text] [Related]
37. Biallelic
Wineland D; Le AN; Hausler R; Kelly G; Barrett E; Desai H; Wubbenhorst B; Pluta J; Bastian P; Symecko H; D'Andrea K; Doucette A; Gabriel P; Reiss KA; Nayak A; Feldman M; Domchek SM; Nathanson KL; Maxwell KN; ;
JCO Precis Oncol; 2023 Aug; 7():e2300036. PubMed ID: 37535879
[TBL] [Abstract][Full Text] [Related]
38. Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study.
Yoshihara K; Baba T; Tokunaga H; Nishino K; Sekine M; Takamatsu S; Matsumura N; Yoshida H; Kajiyama H; Shimada M; Kagimura T; Oda K; Sasajima Y; Yaegashi N; Okamoto A; Sugiyama T; Enomoto T
Cancer Sci; 2023 Jun; 114(6):2515-2523. PubMed ID: 36747324
[TBL] [Abstract][Full Text] [Related]
39. Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic Profiling.
Denkert C; Romey M; Swedlund B; Hattesohl A; Teply-Szymanski J; Kommoss S; Kaiser K; Staebler A; du Bois A; Grass A; Knappmeyer C; Heitz F; Solimeno C; Ebel T; Harter P; Marmé F; Jank P; Gaiser T; Neff C; Wagner U; Timms KM; Rodepeter F
J Mol Diagn; 2022 Dec; 24(12):1254-1263. PubMed ID: 36191839
[TBL] [Abstract][Full Text] [Related]
40. Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
Kadouri L; Rottenberg Y; Zick A; Hamburger T; Lipson D; Peretz T; Nechushtan H
Lung Cancer; 2019 Nov; 137():48-51. PubMed ID: 31542568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
